Provectus Pharmaceuticals Inc. to Report Final Efficacy Data on Melanoma at ESMO 2012
9/19/2012 8:54:06 AM
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that final efficacy data from its Phase 2 trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival "PFS" and overall survival), at the ESMO 2012 (European Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012. These data serve as the basis for planned Phase 3 testing of PV-10 in Stage III melanoma patients with recurrent, in-transit or satellite metastases. A randomized controlled trial to assess PFS against standard care is expected to commence in late 2012 or early 2013 at centers in the USA, Australia and the EU.